JPRN-UMIN000038487招募中未知
SE OF RIFAXIMIN THERAPY IN PRIMARY PREVENTION OF HEPATORENAL SYNDROME IN CIRRHOTIC PATIENTS WITH ASCITES - USE OF RIFAXIMIN THERAPY IN PRIMARY PREVENTION OF HEPATORENAL SYNDROME IN CIRRHOTIC PATIENTS WITH ASCITES
ationalAcademy of health Sciences,Bir Hospital Department Of Medicine Gastroenterology Unit0 个研究点目标入组 94 人开始时间: 2019年11月3日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 94
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Patients with renal impairment (serum creatinine>1.5mg/dl) 2. History of HRS, nephropathy and obstructive Uropathy 3. Recent exposure to radioactive materials and Nephrotoxic drugs 4. Sepsis 5. Hepatocellular carcinoma 6. History of allergic reaction with rifaxmin.
研究者
相似试验
已完成
3 期
Prophylactic Treatment of Travellers' Diarrhoea With RifaximinDiarrhoeaNCT00979056Dr. Philipp Zanger, MD MSc DTM258
招募中
不适用
Multicenter trial for the safety of rifaximin on hepatic encephalopathyhepatic encephalopathyJPRN-UMIN000028637ara Medical University150
招募中
Unknown
Studies on the Efficacy of rifaximin for covert hepatic encephalopathyJPRN-UMIN000050125Kumamoto University60
招募中
不适用
Efficacy and safety of Rifaximin for the treatment of liver cirrhosis with covert hepatic encephalopathyiver cirrhosisJPRN-UMIN000044657Wakayama Medical University40
进行中（未招募）
1 期
Effect of administration of Rifaximin on the increased portal pressure of patients with liver cirrhosis and esophageal varices already treated with propranololEUCTR2014-000102-35-ITClinica Medica 560